Cancer will have no place to hide...
Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies.

Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.

Biotechnology

Health Care

Health Diagnostics

Therapeutics

Myrio Tx

Myrio Tx's headquarters in Blackburn North, Australia

Graeme Wald

Kevin Beasley

Gouri Betigeri

Matthew Beasley

Ben Kiefel

Description

People (6)

Ben Kiefel

Matthew Beasley

Lauren Pitt

Kevin Beasley

Kal Gunarathne

Damian Beasley

Jobs